Editing Statin (section)

===Familial hypercholesterolemia===
Statins may be less effective in reducing LDL cholesterol in people with familial hypercholesterolemia, especially those with [[homozygous]] deficiencies.<ref name="Repas2014"/> These people have defects usually in either the [[LDL receptor]] or [[apolipoprotein B]] genes, both of which are responsible for LDL clearance from the blood.<ref>{{cite journal | vauthors = Ramasamy I | title = Update on the molecular biology of dyslipidemias | journal = Clinica Chimica Acta; International Journal of Clinical Chemistry | volume = 454 | pages = 143–185 | date = February 2016 | pmid = 26546829 | doi = 10.1016/j.cca.2015.10.033 }}</ref> Statins remain a first-line treatment in familial hypercholesterolemia,<ref name="Repas2014">{{cite journal | vauthors = Repas TB, Tanner JR | title = Preventing early cardiovascular death in patients with familial hypercholesterolemia | journal = The Journal of the American Osteopathic Association | volume = 114 | issue = 2 | pages = 99–108 | date = February 2014 | pmid = 24481802 | doi = 10.7556/jaoa.2014.023 | doi-access = free | title-link = doi }}</ref> although other cholesterol-reducing measures may be required.<ref name="Rader2003">{{cite journal | vauthors = Rader DJ, Cohen J, Hobbs HH | title = Monogenic hypercholesterolemia: new insights in pathogenesis and treatment | journal = The Journal of Clinical Investigation | volume = 111 | issue = 12 | pages = 1795–1803 | date = June 2003 | pmid = 12813012 | pmc = 161432 | doi = 10.1172/JCI18925 }}</ref> In people with homozygous deficiencies, statins may still prove helpful, albeit at high doses and in combination with other cholesterol-reducing medications.<ref>{{cite journal | vauthors = Marais AD, Blom DJ, Firth JC | title = Statins in homozygous familial hypercholesterolemia | journal = Current Atherosclerosis Reports | volume = 4 | issue = 1 | pages = 19–25 | date = January 2002 | pmid = 11772418 | doi = 10.1007/s11883-002-0058-7 | s2cid = 8075552 }}</ref>